Notice Number: NOT-DA-19-066
Release Date: August 29, 2019
First Available Due Date: October 5, 2019
Expiration Date: January 8, 2022
PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-055: NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-19-052::NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-19-054: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)
National Institute on Drug Abuse (NIDA)
The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Priority will be given to applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. Approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics like health disparities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and interactions. Analysis of existing data in all Program areas is strongly encouraged.
The mission of the Epidemiology Research Branch is to promote a research Program that is responsive to the evolving/dynamic landscape of drug/substance use. Supported research examines the impact and interplay of individual, familial, behavioral, developmental, socio-cultural/environmental, and community factors on the occurrence and distribution of drug use and associated behaviors and consequences. Studies should be designed to yield information that will guide the development of strategies to reduce the burden of substance use, addiction, and related outcomes on public health.
NIDA seeks applications that allow for the advancement and translation of science and will inform our understanding of drug misuse epidemiology and etiology in a creative and cost-efficient manner. Of particular interest are studies that efficiently combine the advantages of epidemiological samples with behavioral, laboratory-based, biological, neurobiological, and genetic measures, and that address gender differences and health disparities, as well as projects that have the ability to identify and rapidly disseminate information about newly emerging drug trends. Supported research will have substantial public health impact and will inform basic, clinical, prevention, and services research to reduce the burden of drug use, misuse, and addiction on the nation's health.
Research interests include:
Application and Submission Information:
This notice applies to due dates on or after October 5, 2019 and subsequent receipt dates through January 8, 2022.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
For funding consideration, applicants must include "NOT-DA-19-066" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.
Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions: